Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD.


Journal

The Journal of nutritional biochemistry
ISSN: 1873-4847
Titre abrégé: J Nutr Biochem
Pays: United States
ID NLM: 9010081

Informations de publication

Date de publication:
04 2023
Historique:
received: 26 06 2022
revised: 29 09 2022
accepted: 14 11 2022
pubmed: 21 11 2022
medline: 7 3 2023
entrez: 20 11 2022
Statut: ppublish

Résumé

Increased fructose intake from sugar-sweetened beverages and highly processed sweets is a well-recognized risk factor for the development of obesity and its complications. Fructose strongly supports lipogenesis on a normal chow diet by providing both, a substrate for lipid synthesis and activation of lipogenic transcription factors. However, the negative health consequences of dietary sugar are best observed with the concomitant intake of a HFD. Indeed, the most commonly used obesogenic research diets, such as "Western diet", contain both fructose and a high amount of fat. In spite of its common use, how the combined intake of fructose and fat synergistically supports development of metabolic complications is not fully elucidated. Here we present the preponderance of evidence that fructose consumption decreases oxidation of dietary fat in human and animal studies. We provide a detailed review of the mitochondrial β-oxidation pathway. Fructose affects hepatic activation of fatty acyl-CoAs, decreases acylcarnitine production and impairs the carnitine shuttle. Mechanistically, fructose suppresses transcriptional activity of PPARα and its target CPT1α, the rate limiting enzyme of acylcarnitine production. These effects of fructose may be, in part, mediated by protein acetylation. Acetylation of PGC1α, a co-activator of PPARα and acetylation of CPT1α, in part, account for fructose-impaired acylcarnitine production. Interestingly, metabolic effects of fructose in the liver can be largely overcome by carnitine supplementation. In summary, fructose decreases oxidation of dietary fat in the liver, in part, by impairing acylcarnitine production, offering one explanation for the synergistic effects of these nutrients on the development of metabolic complications, such as NAFLD.

Identifiants

pubmed: 36403701
pii: S0955-2863(22)00292-3
doi: 10.1016/j.jnutbio.2022.109224
pii:
doi:

Substances chimiques

Fructose 30237-26-4
acylcarnitine 0
PPAR alpha 0
Carnitine S7UI8SM58A
Dietary Fats 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109224

Subventions

Organisme : NIDDK NIH HHS
ID : K01 DK128022
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001998
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interests The authors declare that there are no conflicts of interest.

Auteurs

Mustafa Kutlu Inci (MK)

Sanko University, School of Medicine, Gaziantep, Turkey.

Se-Hyung Park (SH)

Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY, USA; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA.

Robert N Helsley (RN)

Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY, USA; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA; Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA.

Suzanna L Attia (SL)

Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY, USA.

Samir Softic (S)

Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY, USA; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA; Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: samir.softic@uky.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH